Table 2.

Post-operative chemotherapy treatment characteristics and toxicitiesCaption

Variables	≤3 cycles post-operatively (n=41)	>3 cycles post-operatively (n=59)	P value
Treatment characteristics
Regimen
Carboplatin/paclitaxel every 21 or 28 days	17 (41.5%)	27 (45.8%)	0.49
Carboplatin/weekly paclitaxel or docetaxel	19 (46.3%)	24 (40.7%)
Intraperitoneal chemotherapy	4 (9.8%)	5 (8.5%)
Other	0 (0.0%)	3 (5.3%)
Missing	1 (2.4%)	0 (0.0%)
Post-operative cycles (n)
2	3 (7.3%)	N/A	<0.0001
3	38 (92.7%)	N/A
4	N/A	22 (37.3%)
5	N/A	10 (16.9%)
6	N/A	23 (39.0%)
7	N/A	3 (5.1%)
8	N/A	0 (0.0%)
9	N/A	1 (1.7%)
Median number of total treatment cycles	6	8	<0.0001
Granulocyte colony stimulating factor use
Yes	12 (29.3%)	25 (42.4%)	0.23
No	20 (48.8%)	19 (32.2%)
Missing	9 (22.0%)	14 (25.4%)
Dose delay ≥7 days
Yes	12 (29.3%)	23 (39.0%)	0.57
No	20 (48.8%)	23 (39.0%)
Missing	9 (22.0%)	13 (22.0%)
Dose reduction
Yes	12 (29.3%)	16 (27.1%)	0.54
No	13 (31.7%)	25 (42.4%)
Missing	16 (39.0%)	18 (30.5%)
Toxicities*
Neutropenia
Yes	11 (26.8%)	11 (18.6%)	0.73
No	18 (43.9%)	28 (47.5%)
Missing	12 (29.3%)	20 (33.9%)
Thrombocytopenia
Yes	6 (14.6%)	4 (6.8%)	0.60
No	23 (56.1%)	35 (59.3%)
Missing	12 (29.3%)	20 (33.9%)
Anemia
Yes	4 (9.8%)	9 (15.3%)	0.68
No	25 (61.0%)	30 (50.8%)
Missing	12 (29.3%)	20 (33.9%)
Fatigue
Yes	6 (14.6%)	8 (13.6%)	0.75
No	23 (56.1%)	29 (49.2%)
Missing	12 (29.3%)	22 (37.3%)
Nausea/vomiting
Yes	1 (2.4%)	7 (11.9%)	0.22
No	28 (68.3%)	31 (52.5%)
Missing	12 (29.3%)	21 (35.6%)
Diarrhea
Yes	0 (0.0%)	1 (1.7%)	0.62
No	29 (70.7%)	36 (61.0%)
Missing	12 (29.3%)	22 (37.3%)
Neuropathy
Yes	5 (12.2%)	16 (27.1%)	0.23
No	24 (58.5%)	25 (42.4%)
Missing	12 (29.3%)	18 (30.5%)
Allergic reaction
Yes	1 (2.4%)	0 (0.0%)	0.50
No	28 (68.3%)	37 (62.7%)
Missing	12 (29.3%)	22 (37.3%)
Other†
Yes	4 (9.8%)	10 (16.9%)	0.58
No	25 (61.0%)	29 (49.2%)
Missing	12 (29.3%)	20 (33.9%)

Values shown as n (%).

^*All toxicities grade 2 or higher.

^†Included acute kidney injury, anorexia, constipation, phlebitis, abdominal pain.

N/A, not applicable.